Cefiderocol Dosing in Patients with Acute Burn Injuries
This study is looking at how the antibiotic cefiderocol moves through the bodies of patients who have recently experienced severe burn injuries. Cefiderocol is a powerful medicine used to treat serious infections. We want to understand if the usual doses of cefiderocol work effectively in burn patients, who can process medicines differently. The study will help determine the best dose and schedule for cefiderocol in this group to fight infections and prevent antibiotic resistance. You may be able to join if you are between 18 and 80 years old and have good kidney function. The study is currently unclear on its recruitment status and aims to enroll 12 patients.
- Study design
- This is an interventional study with 12 participants. It is a single-arm study, meaning all participants will receive the same treatment.
- What's involved
- You would receive cefiderocol as part of your treatment. Six blood samples would be drawn from you, depending on your dosing schedule.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety will be monitored daily up to and through the sampling period, which averages 3 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Appropriateness of package insert-stated dosing regimensthrough study completion, an average of 3 days
Steady state blood samples will be collected and analyzed to establish concentration time profiles. Models will be established using body size, renal function, and severity of injury. Dosing regimens will be constructed and tested via Monte Carlo simulation to determine the probability of cefiderocol regimen achieving the fT\>MIC threshold for P.aeruginosa at 75% and 100% fT\>MIC.